Lung Foundation Australia is pleased by the positive recommendation for the listing of Tagrisso on the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic EGFR T790M mutation positive non-small cell lung cancer (NCSLC).
The Lung Foundation advocates for affordable access to new and proven medications for people living with a lung disease, and strongly encourages the patient community to have their voice heard in the process.
The Pharmaceutical Benefits Advisory Committee (PBAC) is now accepting submissions in relation to another lung cancer treatment listing. At the March 2019 PBAC meeting Atezolizumab and Bevacizumab – Tecentriq and Avastin will be considered for reimbursement.
The combination medication is for the treatment of two groups of patients with metastatic non-squamous non-small cell lung cancer:
- Patients who do not have oncogenic drivers (EGFR wild type/ ALK negative population); and
- Patients who do have these drivers (EGFR mutant/ALK positive population) where platinum-doublet chemotherapy is used as a later-line treatment option following targeted (TKI) treatments.
Submissions are also open for changes to accessing Alectinib – Alecensa including an increase in the maximum number of repeats from 1 to 5.
As part of the PBAC process, patients, carers, community members and health professionals are encouraged to make submissions in relation to the listing.
Lung Foundation Australia Advocacy and Policy Manager, Judy Powell said, “the consumer voice is very important in this decision-making process and the Lung Foundation hopes for participation from a variety of individuals, including those who received the combination medicine as part of the Impower150 clinical trial in Australia.”
The Lung Foundation developed a simple step-by-step guide to support consumers in making a submission. Click here to view the documents.
Submissions close on 13 February 2019 and can be made online, via email or post.